Acromegaly Treatment Market size is Anticipated to Reach USD 2.10 Billion by 2025: Grand View Research, Inc.

19-Mar-2020: The global acromegaly treatment market size is expected to reach USD 2.10 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.5% over the forecast period. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

In depth research report on Acromegaly Treatment Market

https://www.grandviewresearch.com/industry-analysis/acromegaly-treatment-market

Further key findings from the report suggest:

·       Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product

·       Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment

·       North America held the dominant market share in 2018, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly

·       Asia Pacific acromegaly treatment market is anticipated to witness lucrative growth in near future due to rising healthcare expenditure and R&D initiatives by pharmaceutical companies

·       Some of the key players are Novartis AG; Ipsen Pharma; Pfizer Inc.; and Chiasma Inc.

Grand View Research has segmented the global acromegaly treatment market on the basis of product, end use and region:

Acromegaly Treatment Product Outlook (Revenue, USD Million, 2014 - 2025)

·       Somatostatin Analogs

·       GHRA

·       Others

Acromegaly Treatment End Use Outlook (Revenue, USD Million, 2014 - 2025)

·       Hospitals & Clinics

·       Others

Browse more research reports of this category:

https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is the U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more market analysis reports, please visit: http://www.grandviewresearch.com/

What will be the upcoming trends in Aromatherapy Carrier Oil Market?

13-Mar-2020: The global aromatherapy carrier oil market is expected to account for USD 1.90 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10%. Growing awareness and increasing use of therapeutic carrier oils has led to high market growth. Aromatherapy is considered an alternative to medicinal therapy for treatment of a wide range of conditions. Thus, with growing awareness about the field of alternative & complementary medicine, therapeutic-grade carrier oils are increasingly being adopted due to their healing properties.

In addition, adoption of natural products has increased as a number of adverse effects are associated with pharmaceutical products. For instance, apricot kernel oil is widely used for skin & hair care and scar & pain management as well as in manufacturing of soaps.

Aromatherapy products such as carrier oils have also been proven to be highly effective in pain management and healing of wounds & cuts. These products consist of healing as well as antibacterial properties.

 In depth research report on Aromatherapy Carrier Oil Market  

https://www.grandviewresearch.com/industry-analysis/aromatherapy-carrier-oil-market

Further key findings from the study suggest:

·       Cosmetics segment dominated the aromatherapy carrier oils market in 2018 and is anticipated to grow at a lucrative rate during the forecast period owing to increase in incidence of skin and hair problems

·       Medical segment also held significant share in 2018 owing to growing awareness about the various types of therapeutic-grade products available

·       Rapid industrialization and increasing consumer awareness regarding new medical practices have led to an increase in demand for these products globally

·       In 2018, personal care segment was expected to witness lucrative CAGR over the forecast period owing to increase in use of carrier oils as a base for manufacturing soaps

·       North America held the largest market share in 2018 owing to rise in the number of key players introducing therapeutic grade products in the U.S.

·       Lucrative trading opportunities have led to an increase in growth potential of the European market

·       Asia Pacific is projected to exhibit significant growth rate over the forecast period due to growing awareness pertaining to aromatherapy as well as rise in incidence of skin disorders in this region

·       Some of the key companies are Edens Garden, Rocky Mountain Oils, Plant Therapy Essential Oils, Falcon Essential Oils, FLORIHANA, and Moksha Lifestyle Products

Grand View Research has segmented the aromatherapy carrier oils market on the basis of application and region:

Aromatherapy Carrier Oils Application Outlook (Revenue, USD Million, 2015 - 2026)

·       Cosmetic

·       Skin Care

·       Others

·       Personal Care

·       Household

·       Soap

·       Food & Beverages

·       Medical

·       Pain Management

·       Cold & Cough

·       Others

Browse more research reports of this category:

https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is the U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more market analysis reports, please visit: http://www.grandviewresearch.com/

Cold Pain Therapy Market Size is Expected to Reach USD 2.3 Billion by 2026: Grand View Research.Inc.

7-Jan-2020: The global cold pain therapy market size is expected to reach USD 2.3 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 4.9%. Rising incidence of orthopedic diseases has led to high growth of the market. CDC estimated that nearly 78 million people in the U.S., aged 18 years or above, are expected to be diagnosed with arthritis by 2040.

Rising number of road accidents and traumatic injuries is leading to a high growth of the market. According to WHO data, every year nearly 10 million people suffer injuries in road accidents or incur a disability as a result of injuries in head, chest, arms, and legs. Thus, with the increasing number of road accidents, the demand for therapy products for pain management is rising. Increasing number of sports injuries also play a pivotal role in the rising demand for these products. The most common types of sport injuries are dislocated joints, muscle sprains & strains, tear of ligaments & tendons that hold the joints together, and fractured bones, including the vertebrae.

Geriatric population is a significant target population driving the market. Countries such as Germany and China have high geriatric population base. This factor is contributing to market growth. According to CDC, 1 in every 4 adults are affected by osteoarthritis. Thus, rising geriatric population is expected to increase the demand for cold pain therapy products.

In depth research report on Cold Pain Therapy Market

https://www.grandviewresearch.com/industry-analysis/cold-pain-therapy-market

Further key findings from the study suggest:

·       OTC products dominated the market in 2018 due to affordability and easy availability of products such as creams, gels, sprays, and roll-ons

·       Orthopedic conditions held a significant market share in 2018 owing to rising prevalence of various musculoskeletal and joint disorders, such as osteoarthritis

·       The sports medicine segment is expected to witness a significant growth during the forecast period due to increasing number of sport-related injuries

·       Retail pharmacies accounted for a considerable revenue share in 2018, owing to increase in their demand due to easy availability of products

·       Among all distribution channels, e-commerce is expected to grow at the highest CAGR during the forecast period, owing to lucrative offers and discounts available online

·       North America dominated the cold pain therapy market in 2018 due to factors such as an increase in the prevalence of orthopedic disorders and presence of key market players in the region

·       Asia Pacific is likely to grow at a high rate over the forecast period due to rising geriatric population, coupled with growing healthcare awareness in the region

·       Some of the major companies in the market are Beiersdorf; Breg, Inc.; DJO Global; Hisamitsu Pharmaceutical Co., Inc.; Johnson & Johnson; and Össur Corporate.

Grand View Research has segmented the cold pain therapymarket on the basis of product, application, distribution channel, and region:

Cold Pain Therapy Product Outlook (Revenue, USD Million, 2015 - 2026)

·       OTC Products

·       Gels, Ointments, & Creams

·       Sprays & Foams

·       Patches

·       Roll-Ons

·       Cold Packs

·       Others

·       Prescription Products

·       Motorized Devices

·       Non-motorized Devices

Cold Pain Therapy Application Outlook (Revenue, USD Million, 2015 - 2026)

·       Orthopedic Conditions

·       Post-operative Therapy

·       Sports Medicine

·       Post-trauma Therapy

Cold Pain Therapy Distribution Channel Outlook (Revenue, USD Million, 2015 - 2026)

·       Hospital Pharmacy

·       Retail Pharmacy

·       E-commerce

Browse more research reports of this category:

https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is the U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more market analysis reports, please visit: http://www.grandviewresearch.com/

Opioid Use Disorder Market Size Hit USD 4.5 billion by 2026: Grand View Research, inc.

7th-Jan-2020: The global opioid use disorder market size is expected to reach USD 4.5 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10.1% over the forecast period. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

 In depth research report on Opioid Use Disorder Market

https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market

Further key findings from the report suggest:

·       Buprenorphine was the largest revenue generating segment in 2018. Its sublingual tablets and branded drug Suboxone are the most widely prescribed drug for OUD

·       Suboxone is the highest prescribed drug in the OUD market, mostly due to its excellent clinical profile

·       Sublocade, a buprenorphine product, is estimated to be the largest and fastest growing product over the forecast period, as it is the first long-acting buprenorphine and the first once-monthly product

·       North America generated the highest revenue in 2018, followed by Europe

·       Some of the major players in the opioid use disorder market include are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, and Omeros

·       The key players are adopting strategies such as mergers and acquisitions, product development, product extension, and regional expansion to increase their market share

·       In 2018, Orexo AB announced that it obtained the rights to commercialize Zubsolv in all the territories outside the U.S. from its current partner Mundipharma

Grand View Research has segmented the opioid use disorder market on the basis of drug and region:

Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2015 - 2026)

·       Buprenorphine

·       Bunavail

·       Sublocade

·       Suboxone

·       Zubsolv

·       Others

·       Methadone

·       Naltrexone

Browse more research reports of this category:

https://www.grandviewresearch.com/industry/homecare-and-decor

About Grand View Research

Grand View Research, Inc. is the U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more market analysis reports, please visit: http://www.grandviewresearch.com/

Irritable Bowel Syndrome Treatment Market Hit USD 3.3 billion by 2026: Grand View Research, Inc.

26-Nov-2019: The global irritable bowel syndrome treatment market size is expected to reach USD 3.3 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a 10.1% CAGR during the forecast period. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient’s professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient’s professional and personal activities, and usually limits an individual’s potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

 In depth research report on Irritable Bowel Syndrome Treatment Market

https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market

Further key findings from the report suggest:

·       IBS-C was the largest revenue generating segment by type in 2018 due to growing prevalence and increasing uptake of drugs such as Linzess/Constella and Amitiza

·       Linzess/Constella led the global IBS treatment market by product in 2018 due to increasing adoption of the product in major regions such as U.S., Germany, U.K., Italy, Spain, and Japan

·       North America was estimated to be the largest revenue generating region in 2018, followed by Europe. Major factors contributing to its dominant share are presence of key market players, high patient awareness, strong presence of novel products, and well-established healthcare infrastructure

·       Europe is projected to be the fastest growing region over the forecast period. Rising commercialization of products and presence of a large target population are driving the IBS treatment market

·       Some of the major players are Allergan; Ironwood Pharmaceuticals, Inc.; Astellas Pharma, Inc.; AstraZeneca; Takeda Pharmaceutical Company Limited; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Ardelyx; and Bausch Health

·       Players have bene adopting strategies such as product extension, product development, regional expansion, and mergers and acquisitions to increase their market share. Bausch Health acquired Salix Pharmaceuticals in April 2015 to expand its portfolio with a focus on gastrointestinal drugs.

Grand View Research has segmented the IBS treatment market based on type, drug, and region:

Irritable Bowel Syndrome Treatment Type Outlook (Revenue, USD Million, 2014 - 2026)

·       IBS-C

·       Linzess/Constella

·       Amitiza

·       Others

·       IBS-D

·       Xifaxan

·       Viberzi

·       Others

Irritable Bowel Syndrome Treatment Product Outlook (Revenue, USD Million, 2014 - 2026)

·       Xifaxan

·       Linzess/Constella

·       Viberzi

·       Amitiza

·       Others

Browse more research reports of this category:

https://www.grandviewresearch.com/industry/pharmaceuticals

About Grand View Research

Grand View Research, Inc. is the U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For more market analysis reports, please visit: http://www.grandviewresearch.com/